


### In the Claims

This listing of claims will replace all prior versions and listings of claims in the patent application.

1-3. (Canceled)

4. (Currently Amended) A compound ~~selected from the group consisting of a compound of the general formula I<sub>C1</sub>~~



wherein

A represents hydrogen[;], alkyl[;], halogen or cyano;

B represents hydrogen[;], alkyl or halogen;

R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup> and R<sup>4</sup> independently represent hydrogen[;], alkyl[;], halogen[;], nitro[;], cyano or formyl; and

R<sup>5</sup> and R<sup>6</sup> independently represent hydrogen[;], alkyl[;], cycloalkyl[;], cycloalkyl-alkyl[;], heteroaryl[;], heteroaryl-alkyl[;], alkenyl[;], carboxyalkyl[;], cyanoalkyl[;], diphenylalkyl[;], aryl, aryl-alkoxy-aryl, aryl-alkyl, aryl-alkyl-aryl, arylcarbonyl-aryl or aryloxy-aryl, or [[R5]] R<sup>5</sup> and [[R6]] R<sup>6</sup>, together with the nitrogen atom to which they are attached, form a heterocyclic ring system;

~~and an optically pure enantiomer, a mixture of enantiomers, a racemate, an optically pure diastereoisomer, a mixture of diastereoisomers, a diastereoisomeric racemate, a mixture of~~

diastereoisomeric racemates, a meso form, a geometric isomer, a prodrug form, a solvate or a morphological form, or a salt of the the [[a]] compound of general formula I<sub>C1</sub>;

with the proviso that the compound is not exception of the following compounds:

- {3-[(E)-2-cyano-2-(4-fluoro-phenylcarbamoyl)-vinyl]-indol-1-yl}-acetic acid;
- {3-((E)-2-cyano-2-m-tolylcarbamoyl-vinyl)-indol-1-yl}-acetic acid;
- {3-[(E)-2-(3-bromo-phenylcarbamoyl)-2-cyano-vinyl]-indol-1-yl}-acetic acid;
- {3-((E)-2-cyano-2-phenylcarbamoyl-vinyl)-indol-1-yl}-acetic acid;
- {3-((E)-2-benzylcarbamoyl-2-cyano-vinyl)-indol-1-yl}-acetic acid;
- {3-((E)-2-cyano-2-o-tolylcarbamoyl-vinyl)-indol-1-yl}-acetic acid;
- {3-((E)-2-cyano-2-p-tolylcarbamoyl-vinyl)-indol-1-yl}-acetic acid;
- {3-[(E)-2-(4-bromo-phenylcarbamoyl)-2-cyano-vinyl]-indol-1-yl}-acetic acid;
- {3-[(E)-2-cyano-2-(4-ethyl-phenylcarbamoyl)-vinyl]-indol-1-yl}-acetic acid;
- {3-[(E)-2-cyano-2-(4-methoxy-phenylcarbamoyl)-vinyl]-indol-1-yl}-acetic acid;
- {3-[(E)-2-cyano-2-(4-ethoxy-phenylcarbamoyl)-vinyl]-indol-1-yl}-acetic acid;
- {3-((E)-2-cyano-2-isopropylcarbamoyl-vinyl)-indol-1-yl}-acetic acid;
- {3-[(E)-2-cyano-2-(3-ethoxy-phenylcarbamoyl)-vinyl]-indol-1-yl}-acetic acid;
- {3-[(E)-2-cyano-3-[(2-(1H-indol-3-yl)ethyl)amino]-3-oxo-1-propenyl]-indol-1-yl}-acetic acid;
- {3-[(E)-2-cyano-2-(4-chloro-phenylcarbamoyl)-vinyl]-indol-1-yl}-acetic acid;
- {3-[(E)-2-cyano-3-(4-methyl-piperidin-1-yl)-3-oxo-propenyl]-indol-1-yl}-acetic acid;
- {3-[(E)-2-(3-chloro-4-methyl-phenylcarbamoyl)-2-cyano-vinyl]-indol-1-yl}-acetic acid;
- {3-[(E)-2-cyano-2-(3-phenyl-propylcarbamoyl)-vinyl]-indol-1-yl}-acetic acid;
- {3-[(E)-2-cyano-2-(2,3-dichloro-phenylcarbamoyl)-vinyl]-indol-1-yl}-acetic acid;
- {3-[(E)-2-(5-chloro-2-methyl-phenylcarbamoyl)-2-cyano-vinyl]-indol-1-yl}-acetic acid;
- {3-[(E)-2-cyano-2-(4-methoxy-benzylcarbamoyl)-vinyl]-indol-1-yl}-acetic acid;
- {3-[(E)-2-cyano-2-(2-fluoro-phenylcarbamoyl)-vinyl]-indol-1-yl}-acetic acid; or and
- {3-[(E)-2-cyano-3-oxo-3-(4-phenyl-piperazin-1-yl)-propenyl]-indol-1-yl}-acetic acid.

5. (Currently Amended) The [[A]] compound according to claim 4, wherein:

- ❖ A is cyano;
- ❖ B is hydrogen;

- ❖  $R^1$ ,  $R^2$ ,  $R^3$  and  $R^4$  are all hydrogen atoms or one of  $R^1$ ,  $R^2$ ,  $R^3$  and  $R^4$  is halogen while the others are all hydrogen; and
- ❖  $R^5$  is ~~selected from the group consisting of heteroaryl-alkyl, diphenylalkyl, aryl, aryl-alkoxy-aryl, aryl-alkyl, aryl-alkyl-aryl, arylcarbonyl-aryl or and aryloxy-aryl~~, wherein the aryl, aryl-alkoxy-aryl, aryl-alkyl, aryl-alkyl-aryl, arylcarbonyl-aryl and aryloxy-aryl are such that their aryl groups are unsubstituted or substituted 1 or 2 times with substituents independently represented by selected from the group consisting of halogen, alkoxy, haloalkoxy or and alkylcarbonyl; and  $R^6$  is ~~selected from the group consisting of~~ alkyl, alkenyl, cycloalkyl, aryl, arylalkyl or and cyanoalkyl, wherein the aryl and aryl-alkyl are such that their aryl groups are unsubstituted or substituted 1 or 2 times with substituents independently represented by selected from the group consisting of halogen, alkoxy, haloalkoxy or and alkylcarbonyl; or  $R^5$  and  $R^6$ , together with the nitrogen atom to which they are attached, form a dihydrophenanthridine, dihydroacridine, dihydrodibenzoazocine, dihydrodibenzoazepine, dihydroindole, dihydroquinoline, dibenzoazepine, phenothiazine, oxa-aza-dibenzocycloheptene, or dihydroisoquinoline ring, which may be unsubstituted or substituted with one substituent represented by selected from halogen, methyl, methoxy or and trifluoromethyl.
6. (Currently Amended) The [[A]] compound according to claim 4, wherein the groups  $R^5$  and  $R^6$  do not form a heterocyclic ring system together with the nitrogen atom to which they are attached.
7. (Currently Amended) The [[A]] compound according to claim 6, wherein  $R^5$  is aryl and  $R^6$  is ~~selected from the group consisting of~~ alkyl, cycloalkyl, alkenyl, cyanoalkyl, diphenylalkyl, heteroaryl-alkyl, aryl-alkyl or and aryl.
8. (Currently Amended) The [[A]] compound according to claim 6, wherein  $R^5$  is aryl-alkyl and  $R^6$  is ~~selected from the group consisting of~~ alkyl, aryl or and aryl-alkyl.
9. (Currently Amended) The [[A]] compound according to claim 4, wherein the groups  $R^5$  and  $R^6$  form a heterocyclic ring system together with the nitrogen atom to which they are attached.
10. (Currently Amended) The [[A]] compound according to claim 4, wherein the compound is which is selected from the group consisting of:

- {3-[(E)-2-cyano-2-(cyclohexylmethyl-carbamoyl)-vinyl]-indol-1-yl}-acetic acid;
- {3-[(E)-2-cyano-2-phenethylcarbamoyl-vinyl]-indol-1-yl}-acetic acid;
- {3-[(E)-2-cyano-2-isopropylcarbamoyl-vinyl]-indol-1-yl}-acetic acid;
- {3-[(E)-2-cyano-2-propylcarbamoyl-vinyl]-indol-1-yl}-acetic acid;
- {3-[(E)-2-cyano-2-cyclohexylcarbamoyl-vinyl]-indol-1-yl}-acetic acid;
- {3-[(E)-2-cyano-2-(3-methyl-butylcarbamoyl)-vinyl]-indol-1-yl}-acetic acid;
- {3-[(E)-2-(benzyl-phenyl-carbamoyl)-2-cyano-vinyl]-indol-1-yl}-acetic acid;
- {3-[(E)-2-cyano-2-(4-cyano-phenylcarbamoyl)-vinyl]-indol-1-yl}-acetic acid;
- {3-[(E)-2-cyano-2-(4-fluoro-phenylcarbamoyl)-vinyl]-indol-1-yl}-acetic acid;
- {3-[(E)-2-cyano-2-(4-phenoxy-phenylcarbamoyl)-vinyl]-indol-1-yl}-acetic acid;
- {3-[(E)-2-cyano-2-(naphthalen-2-ylcarbamoyl)-vinyl]-indol-1-yl}-acetic acid;
- {3-[(E)-2-cyano-2-(2-isopropyl-phenylcarbamoyl)-vinyl]-indol-1-yl}-acetic acid;
- {3-[(E)-2-cyano-2-(4-isopropyl-phenylcarbamoyl)-vinyl]-indol-1-yl}-acetic acid;
- {3-[(E)-2-cyano-2-(3-methoxy-phenylcarbamoyl)-vinyl]-indol-1-yl}-acetic acid;
- {3-[(E)-2-cyano-2-(3-fluoro-phenylcarbamoyl)-vinyl]-indol-1-yl}-acetic acid;
- {3-[(E)-2-cyano-2-(9H-fluoren-2-ylcarbamoyl)-vinyl]-indol-1-yl}-acetic acid;
- {3-[(E)-2-cyano-2-(4-propyl-phenylcarbamoyl)-vinyl]-indol-1-yl}-acetic acid;
- {3-[(E)-2-(biphenyl-4-ylcarbamoyl)-2-cyano-vinyl]-indol-1-yl}-acetic acid;
- {3-[(E)-2-cyano-2-(3,5'-dimethyl-biphenyl-4-ylcarbamoyl)-vinyl]-indol-1-yl}-acetic acid;
- {3-[(E)-2-(4-tert-butyl-phenylcarbamoyl)-2-cyano-vinyl]-indol-1-yl}-acetic acid;
- {3-[(E)-2-(2-benzyl-phenylcarbamoyl)-2-cyano-vinyl]-indol-1-yl}-acetic acid;
- {3-[(E)-2-(4-butyl-phenylcarbamoyl)-2-cyano-vinyl]-indol-1-yl}-acetic acid;
- {3-[(E)-2-(2-acetyl-phenylcarbamoyl)-2-cyano-vinyl]-indol-1-yl}-acetic acid;
- {3-[(E)-2-cyano-2-(indan-5-ylcarbamoyl)-vinyl]-indol-1-yl}-acetic acid;
- {3-[(E)-2-(4-Sec-butyl-phenylcarbamoyl)-2-cyano-vinyl]-indol-1-yl}-acetic acid;
- {3-[(E)-2-cyano-2-(2-propyl-phenylcarbamoyl)-vinyl]-indol-1-yl}-acetic acid;
- {3-[(E)-2-cyano-2-(3-phenoxy-phenylcarbamoyl)-vinyl]-indol-1-yl}-acetic acid;
- {3-[(E)-2-cyano-2-(3-ethyl-phenylcarbamoyl)-vinyl]-indol-1-yl}-acetic acid;
- {3-[(E)-2-cyano-2-(2-ethoxy-phenylcarbamoyl)-vinyl]-indol-1-yl}-acetic acid;
- {3-[(E)-2-(3-benzyloxy-phenylcarbamoyl)-2-cyano-vinyl]-indol-1-yl}-acetic acid;

- {3-[(E)-2-cyano-2-(4-iodo-phenylcarbamoyl)-vinyl]-indol-1-yl}-acetic acid;
- {3-[(E)-2-cyano-2-(3-iodo-phenylcarbamoyl)-vinyl]-indol-1-yl}-acetic acid;
- {3-[(E)-2-cyano-2-[(4-fluoro-phenyl)-methyl-carbamoyl]-vinyl]-indol-1-yl}-acetic acid;
- {3-[(E)-2-cyano-2-[(4-methoxy-phenyl)-methyl-carbamoyl]-vinyl]-indol-1-yl}-acetic acid;
- {3-[(E)-2-cyano-2-(methyl-phenyl-carbamoyl)-vinyl]-indol-1-yl}-acetic acid;
- {3-[(E)-2-cyano-3-(3,4-dihydro-2H-quinolin-1-yl)-3-oxo-propenyl]-indol-1-yl}-acetic acid;
- {3-[(E)-2-cyano-2-(methyl-p-tolyl-carbamoyl)-vinyl]-indol-1-yl}-acetic acid;
- {3-[(E)-2-cyano-2-[2-(2,4-dichloro-phenoxy)-phenylcarbamoyl]-vinyl]-indol-1-yl}-acetic acid;
- {3-[(E)-2-cyano-2-(2,5-dimethyl-phenylcarbamoyl)-vinyl]-indol-1-yl}-acetic acid;
- {3-[(E)-2-cyano-2-(9-ethyl-9H-carbazol-3-ylcarbamoyl)-vinyl]-indol-1-yl}-acetic acid;
- {3-[(E)-2-(3,5-bis-trifluoromethyl-phenylcarbamoyl)-2-cyano-vinyl]-indol-1-yl}-acetic acid;
- {3-[(E)-2-cyano-2-(5-methoxy-2-methyl-phenylcarbamoyl)-vinyl]-indol-1-yl}-acetic acid;
- {3-[(E)-2-(3-benzoyl-phenylcarbamoyl)-2-cyano-vinyl]-indol-1-yl}-acetic acid;
- {3-[(E)-2-(4-benzyloxy-phenylcarbamoyl)-2-cyano-vinyl]-indol-1-yl}-acetic acid;
- {3-[(E)-2-cyano-2-(3-nitro-phenylcarbamoyl)-vinyl]-indol-1-yl}-acetic acid;
- {3-[(E)-2-cyano-2-(9-oxo-9H-fluoren-2-ylcarbamoyl)-vinyl]-indol-1-yl}-acetic acid;
- {3-[(E)-2-cyano-2-(4-methoxy-biphenyl-3-ylcarbamoyl)-vinyl]-indol-1-yl}-acetic acid;
- {3-[(E)-2-cyano-2-(2-methoxy-dibenzofuran-3-ylcarbamoyl)-vinyl]-indol-1-yl}-acetic acid;
- {3-[(E)-2-cyano-2-(9-oxo-9H-fluoren-4-ylcarbamoyl)-vinyl]-indol-1-yl}-acetic acid;
- {3-[(E)-2-cyano-2-(9-oxo-9H-fluoren-1-ylcarbamoyl)-vinyl]-indol-1-yl}-acetic acid;
- {3-[(E)-2-(2-benzoyl-phenylcarbamoyl)-2-cyano-vinyl]-indol-1-yl}-acetic acid;
- {3-[(E)-2-(3-chloro-4-methoxy-phenylcarbamoyl)-2-cyano-vinyl]-indol-1-yl}-acetic acid;
- {3-[(E)-2-(5-chloro-2-methoxy-phenylcarbamoyl)-2-cyano-vinyl]-indol-1-yl}-acetic acid;
- 3-[(E)-3-(1-carboxymethyl-1H-indol-3-yl)-2-cyano-acryloylamino]-4-methyl-benzoic acid methyl ester;
- 2-[(E)-3-(1-carboxymethyl-1H-indol-3-yl)-2-cyano-acryloylamino]-benzoic acid methyl ester;
- {3-[(E)-2-cyano-2-(4-trifluoromethoxy-phenylcarbamoyl)-vinyl]-indol-1-yl}-acetic acid;
- {3-[(E)-2-cyano-2-(3,5-dimethyl-phenylcarbamoyl)-vinyl]-indol-1-yl}-acetic acid;
- {3-[(E)-2-(3-bromo-4-methyl-phenylcarbamoyl)-2-cyano-vinyl]-indol-1-yl}-acetic acid;
- {3-[(E)-2-(4-bromo-3-methyl-phenylcarbamoyl)-2-cyano-vinyl]-indol-1-yl}-acetic acid;

- 4-[(E)-3-(1-carboxymethyl-1H-indol-3-yl)-2-cyano-acryloylamino]-benzoic acid ethyl ester;
- 3-[(E)-3-(1-carboxymethyl-1H-indol-3-yl)-2-cyano-acryloylamino]-benzoic acid methyl ester;
- { 3-[(E)-2-cyano-2-(4-trifluoromethyl-phenylcarbamoyl)-vinyl]-indol-1-yl}-acetic acid;
- {3-[(E)-2-cyano-2-(3,5-dimethoxy-phenylcarbamoyl)-vinyl]-indol-1-yl}-acetic acid;
- {3-[(E)-2-(4-bromo-3-chloro-phenylcarbamoyl)-2-cyano-vinyl]-indol-1-yl}-acetic acid;
- {3-[(E)-2-(4-bromo-2-methyl-phenylcarbamoyl)-2-cyano-vinyl]-indol-1-yl}-acetic acid;
- {3-[(E)-2-(4-acetyl-phenylcarbamoyl)-2-cyano-vinyl]-indol-1-yl}-acetic acid;
- {3-[(E)-2-(2-bromo-4-methyl-phenylcarbamoyl)-2-cyano-vinyl]-indol-1-yl}-acetic acid;
- {3-[(E)-2-(benzo[1,3]dioxol-5-ylcarbamoyl)-2-cyano-vinyl]-indol-1-yl}-acetic acid;
- {3-[(E)-2-cyano-2-(phenethyl-phenyl-carbamoyl)-vinyl]-indol-1-yl}-acetic acid;
- {3-[(E)-2-cyano-3-(11,12-dihydro-6H-dibenzo[b,f]azocin-5-yl)-3-oxo-propenyl]-indol-1-yl}-acetic acid;
- [3-((E)-2-cyano-2-diphenylcarbamoyl-vinyl)-indol-1-yl]-acetic acid;
- [3-((E)-2-cyano-3-dibenzo[b,f]azepin-5-yl-3-oxo-propenyl)-indol-1-yl]-acetic acid;
- (3-{(E)-2-((4-chloro-phenyl)-methyl-carbamoyl)-2-cyano-vinyl}-indol-1-yl)-acetic acid;
- {3-[(E)-2-cyano-3-(6,11-dihydro-dibenzo[b,e]azepin-5-yl)-3-oxo-propenyl]-indol-1-yl}-acetic acid;
- [3-((E)-2-cyano-2-diphenethylcarbamoyl-vinyl)-indol-1-yl]-acetic acid;
- {3-[(E)-2-cyano-3-(10,11-dihydro-dibenzo[b,f]azepin-5-yl)-3-oxo-propenyl]-indol-1-yl}-acetic acid;
- (3-{(E)-2-cyano-2-[methyl-((R)-1-phenyl-ethyl)-carbamoyl]-vinyl}-indol-1-yl)-acetic acid;
- {3-[(E)-2-(benzyl-methyl-carbamoyl)-2-cyano-vinyl]-indol-1-yl}-acetic acid;
- (3-{(E)-2-[(4-acetyl-phenyl)-methyl-carbamoyl]-2-cyano-vinyl}-indol-1-yl)-acetic acid;
- (3-{(E)-2-[(4-acetyl-phenyl)-furan-2-ylmethyl-carbamoyl]-2-cyano-vinyl}-indol-1-yl)-acetic acid;
- {3-[(E)-2-(benzyl-carboxymethyl-carbamoyl)-2-cyano-vinyl]-indol-1-yl}-acetic acid;
- 3-[benzyl-[(E)-3-(1-carboxymethyl-1H-indol-3-yl)-2-cyano-acryloyl]-amino]-propionic acid;
- {3-[(E)-2-cyano-3-(2,3-dihydro-indol-1-yl)-3-oxo-propenyl]-indol-1-yl}-acetic acid;
- {3-[(E)-2-(carboxymethyl-phenyl-carbamoyl)-2-cyano-vinyl]-indol-1-yl}-acetic acid;
- (3-{(E)-2-cyano-2-[(2-cyano-ethyl)-phenyl-carbamoyl]-vinyl}-indol-1-yl)-acetic acid;


- (3-[(E)-2-[(3-chloro-phenyl)-methyl-carbamoyl]-2-cyano-vinyl]-indol-1-yl)-acetic acid;
- {3-[(E)-2-(allyl-phenyl-carbamoyl)-2-cyano-vinyl]-indol-1-yl}-acetic acid;
- {3-[(E)-2-cyano-2-(cyclohexyl-phenyl-carbamoyl)-vinyl]-indol-1-yl}-acetic acid;
- {3-[(E)-2-cyano-2-(methyl-o-tolyl-carbamoyl)-vinyl]-indol-1-yl}-acetic acid;
- {3-[(E)-2-cyano-2-(ethyl-phenyl-carbamoyl)-vinyl]-indol-1-yl}-acetic acid;
- {3-[(E)-2-(butyl-phenyl-carbamoyl)-2-cyano-vinyl]-indol-1-yl}-acetic acid;
- [5-bromo-3-((E)-2-(cyano-2-phenylcarbamoyl-vinyl)-indol-1-yl)]-acetic acid;
- [3-((E)-2-cyano-2-phenylcarbamoyl-vinyl)-5-fluoro-indol-1-yl]-acetic acid;
- [3-((E)-2-cyano-2-phenylcarbamoyl-vinyl)-5-methyl-indol-1-yl]-acetic acid;
- [3-((E)-2-cyano-2-phenylcarbamoyl-vinyl)-6-fluoro-indol-1-yl]-acetic acid;
- [3-((E)-2-cyano-2-phenylcarbamoyl-vinyl)-6-nitro-indol-1-yl]-acetic acid;
- [3-((E)-2-cyano-2-phenylcarbamoyl-vinyl)-7-methyl-indol-1-yl]-acetic acid;
- {3-[(E)-3-(2-chloro-phenothiazin-10-yl)-2-cyano-3-oxo-propenyl]-indol-1-yl}-acetic acid;
- {3-[(E)-2-cyano-2-(phenyl-thiophen-3-ylmethyl-carbamoyl)-vinyl]-indol-1-yl}-acetic acid;
- (3-[(E)-2-cyano-2-[(2,2-diphenyl-ethyl)-phenyl-carbamoyl]-vinyl]-indol-1-yl)-acetic acid;
- (3-[(E)-2-cyano-2-[phenyl-(3-phenyl-propyl)-carbamoyl]-vinyl]-indol-1-yl)-acetic acid;
- [3-((E)-2-cyano-2-[[2-(4-fluoro-phenyl)-ethyl]-phenyl-carbamoyl]-vinyl]-indol-1-yl]-acetic acid;
- {3-[(E)-2-cyano-3-(11H-10-oxa-5-aza-dibenzo[a,d]cyclohepten-5-yl)-3-oxo-propenyl]-indol-1-yl}-acetic acid;
- {3-[(E)-2-cyano-2-(isopropyl-phenyl-carbamoyl)-vinyl]-indol-1-yl}-acetic acid;
- (3-[(E)-2-cyano-2-[(3,4-dichloro-phenyl)-methyl-carbamoyl]-vinyl]-indol-1-yl)-acetic acid;
- (3-[(E)-2-cyano-2-[ethyl-(4-trifluoromethoxy-phenyl)-carbamoyl]-vinyl]-indol-1-yl)-acetic acid;
- {3-[(E)-2-(benzhydryl-carbamoyl)-2-cyano-vinyl]-indol-1-yl}-acetic acid;
- (3-[(E)-2-cyano-2-[methyl-(2-trifluoromethoxy-phenyl)-carbamoyl]-vinyl]-indol-1-yl)-acetic acid;
- {3-[(E)-2-cyano-2-(2,4-difluoro-phenylcarbamoyl)-vinyl]-indol-1-yl}-acetic acid;
- (3-[(E)-2-cyano-2-[methyl-(4-trifluoromethoxy-phenyl)-carbamoyl]-vinyl]-indol-1-yl)-acetic acid;

- {3-[(E)-2-cyano-2-(ethyl-naphthalen-1-yl-carbamoyl)-vinyl]-indol-1-yl}-acetic acid;
- (3-{(E)-2-cyano-2-[(2,4-difluoro-phenyl)-methyl-carbamoyl]-vinyl}-indol-1-yl)-acetic acid;
- {3-[(E)-2-cyano-2-(2,4,6-trifluoro-phenylcarbamoyl)-vinyl]-indol-1-yl}-acetic acid;
- {3-[(E)-2-cyano-2-(2,3,4-trifluoro-phenylcarbamoyl)-vinyl]-indol-1-yl}-acetic acid;
- {3-[(E)-2-cyano-3-(3,4-dihydro-1H-isoquinolin-2-yl)-3-oxo-propenyl]-indol-1-yl}-acetic acid;
- {3-[(E)-2-cyano-3-oxo-3-(7-trifluoromethyl-3,4-dihydro-2H-quinolin-1-yl)-propenyl]-indol-1-yl}-acetic acid;
- (3-{(E)-2-cyano-2-[(3-fluoro-phenyl)-methyl-carbamoyl]-vinyl}-indol-1-yl)-acetic acid;
- [3-((E)-2-cyano-3-dibenzo[b,f]azepin-5-yl-3-oxo-propenyl)-5-fluoro-indol-1-yl]-acetic acid;
- {3-[(E)-2-cyano-3-(6,11-dihydro-dibenzo[b,e]azepin-5-yl)-3-oxo-propenyl]-5-fluoro-indol-1-yl}-acetic acid;
- {3-[(E)-2-(benzyl-phenyl-carbamoyl)-2-cyano-vinyl]-5-fluoro-indol-1-yl}-acetic acid;
- {3-[(E)-2-cyano-2-(cyclohexyl-phenyl-carbamoyl)-vinyl]-5-fluoro-indol-1-yl}-acetic acid;
- {3-[(E)-2-(butyl-phenyl-carbamoyl)-2-cyano-vinyl]-5-fluoro-indol-1-yl}-acetic acid;
- (3-{(E)-2-cyano-2-[(4-fluoro-phenyl)-methyl-carbamoyl]-vinyl}-5-fluoro-indol-1-yl)-acetic acid;
- (3-{(E)-2-cyano-2-[(3-fluoro-phenyl)-methyl-carbamoyl]-vinyl}-5-fluoro-indol-1-yl)-acetic acid;
- (3-{(E)-2-cyano-2-[(3,4-dichloro-phenyl)-methyl-carbamoyl]-vinyl}-5-fluoro-indol-1-yl)-acetic acid;
- (3-{(E)-2-cyano-2-[methyl-(2-trifluoromethyl-phenyl)-carbamoyl]-vinyl}-5-fluoro-indol-1-yl)-acetic acid;
- (3-{(E)-2-cyano-2-[(2,4-difluoro-phenyl)-methyl-carbamoyl]-vinyl}-5-fluoro-indol-1-yl)-acetic acid;
- {3-[(E)-2-cyano-2-(phenyl-thiophen-3-ylmethyl-carbamoyl)-vinyl]-5-fluoro-indol-1-yl}-acetic acid;
- {3-[(E)-2-cyano-3-oxo-3-(7-trifluoromethyl-3,4-dihydro-2H-quinolin-1-yl)-propenyl]-5-fluoro-indol-1-yl}-acetic acid;
- (3-{(E)-2-cyano-2-[ethyl-(4-trifluoromethoxy-phenyl)-carbamoyl]-vinyl}-5-fluoro-indol-1-yl)-acetic acid;



- {3-[(E)-2-cyano-3-(3,4-dihydro-1H-isoquinolin-2-yl)-3-oxo-propenyl]-5-fluoro-indol-1-yl}-acetic acid;
- {3-[(E)-2-cyano-2-(phenethyl-phenyl-carbamoyl)-vinyl]-5-fluoro-indol-1-yl}-acetic acid;
- {3-[(E)-2-cyano-3-dibenzo[b,f]azepin-5-yl-3-oxo-propenyl]-6-methyl-indol-1-yl}-acetic acid;
- {3-[(E)-2-cyano-3-(6,11-dihydro-dibenzo[b,c]azepin-5-yl)-3-oxo-propenyl]-6-methyl-indol-1-yl}-acetic acid;
- {3-[(E)-2-cyano-3-(10,11-dihydro-dibenzo[b,f]azepin-5-yl)-3-oxo-propenyl]-6-methyl-indol-1-yl}-acetic acid;
- {3-[(E)-2-(benzyl-phenyl-carbamoyl)-2-cyano-vinyl]-6-methyl-indol-1-yl}-acetic acid;
- {3-[(E)-2-cyano-2-(cyclohexyl-phenyl-carbamoyl)-vinyl]-6-methyl-indol-1-yl}-acetic acid;
- {3-[(E)-2-cyano-2-[(4-fluoro-phenyl)-methyl-carbamoyl]-vinyl]-6-methyl-indol-1-yl}-acetic acid;
- {3-[(E)-2-(butyl-phenyl-carbamoyl)-2-cyano-vinyl]-6-methyl-indol-1-yl}-acetic acid;
- {3-[(E)-2-cyano-2-(cyclohexyl-phenyl-carbamoyl)-vinyl]-7-methyl-indol-1-yl}-acetic acid; or
- and
- {3-[(E)-2-cyano-2-[(4-fluoro-phenyl)-methyl-carbamoyl]-vinyl]-7-methyl-indol-1-yl}-acetic acid.

11. (Currently Amended) The [[A]] compound according to claim 4, wherein the compound of formula I<sub>C1</sub> is a compound of formula I<sub>C2</sub>



wherein

A represents hydrogen[(:)], alkyl[(:)], halogen or cyano;

B represents hydrogen[(:)], alkyl or halogen;

R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup> and R<sup>4</sup> independently represent hydrogen[(:)], alkyl[(:)], halogen[(:)], nitro[(:)], cyano or formyl; and

R<sup>5</sup> and R<sup>6</sup> independently represent hydrogen[(:)], alkyl[(:)], cycloalkyl[(:)], cycloalkyl-alkyl[(:)], heteroaryl[(:)], heteroaryl-alkyl[(:)], alkenyl[(:)], carboxyalkyl[(:)], cyanoalkyl[(:)], diphenylalkyl[(:)], aryl, aryl-alkoxy-aryl, aryl-alkyl, aryl-alkyl-aryl, arylcarbonyl-aryl or aryloxy-aryl, or R<sup>5</sup> and R<sup>6</sup>, together with the nitrogen atom to which they are attached, form a heterocyclic ring system;


provided that at least one of the following conditions must be met:

- ❖ one of R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup> and R<sup>4</sup> is different from a hydrogen atom; or
- ❖ when R<sup>5</sup> and R<sup>6</sup> are such that they do not form a heterocyclic ring system together with the nitrogen atom to which they are attached, then both R<sup>5</sup> and R<sup>6</sup> are different from hydrogen and one of R<sup>5</sup> and R<sup>6</sup> is different from alkyl; or
- ❖ when R<sup>5</sup> and R<sup>6</sup> are such that they form a heterocyclic ring system together with the nitrogen atom to which they are attached, then said heterocyclic ring system is neither an unsubstituted or substituted piperidine nor an unsubstituted or substituted piperazine.

12. (Currently Amended) A pharmaceutical composition ~~comprising containing, as active principle,~~ at least one compound according to claim [11]4[(:)] and a pharmaceutically acceptable carrier.

13. (Currently Amended) A method for preventing or treating a chronic or acute allergic immune disorder, comprising administering to a subject in need thereof an effective amount of the compound according to claim [11]4, ~~wherein the disorder is selected from the group consisting of allergic asthma, rhinitis, chronic obstructive pulmonary disease (COPD), dermatitis, inflammatory bowel disease, rheumatoid arthritis, allergic nephritis, conjunctivitis, atopic dermatitis, bronchial asthma, food allergy, systemic mast cell disorders, anaphylactic shock, urticaria, eczema, itching, inflammation, ischemia-reperfusion injury, cerebrovascular disorders, pleuritis, ulcerative colitis, Churg-Strauss syndrome, sinusitis, basophilic leukemia, and basophilic leukocytosis.~~

14. (Cancelled).  
15. (Cancelled).  
16. (Currently Amended) A pharmaceutical composition ~~comprising~~ containing at least one compound of the ~~general~~ Formula I<sub>p</sub>



wherein

A represents hydrogen[[:]], alkyl[[:]], halogen or cyano;

B represents hydrogen[[:]], alkyl or halogen;

R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup> and R<sup>4</sup> independently represent hydrogen[[:]], alkyl[[:]], halogen[[:]], nitro[[:]], cyano or formyl; and

R<sup>5</sup> and R<sup>6</sup> independently represent hydrogen[[:]], alkyl[[:]], alkenyl[[:]], cycloalkyl[[:]], heteroaryl[[:]], or a member represented by ~~selected from the group consisting of~~ aryl, alkoxy-aryl, alkoxycarbonyl-aryl, alkylcarbonyl-aryl, aryl-alkoxy-aryl, aryl-alkyl, aryl-alkyl-aryl, arylcarbonyl-aryl ~~or-and~~ aryloxy-aryl, wherein the aryl group is unsubstituted or mono- or di-substituted substituted with substituent(s) independently represented by ~~selected from the group consisting of~~ alkyl, alkoxy, halogen, cyano, alkoxycarbonyl, alkylcarbonyl, phenyl, benzyl, benzoyl, benzyloxy, benzyloxycarbonyl, trifluoromethyl ~~or-and~~ trifluoromethoxy; or R<sup>5</sup> and R<sup>6</sup>, together with the nitrogen atom to which they are attached, form a heterocyclic ring system; and

optically pure enantiomers, mixtures of enantiomers, racemates, optically pure diastereoisomers, mixtures of diastereoisomers, diastereoisomeric racemates, mixture of diastereoisomeric

racemates, meso forms, geometric isomers, prodrugs of compounds in which a prodrug forming group is present, as well as solvates and morphological forms, pharmaceutically acceptable salts thereof and inert carrier materials or adjuvants;

provided that in ~~general~~ Formula I<sub>p</sub>:

- i) the term "alkyl" or "lower alkyl", used alone or in any combination, refers to a saturated aliphatic group of a straight or branched hydrocarbon chain containing 1-8 carbon atoms which saturated aliphatic group can be optionally substituted with one or more substituents, each independently ~~represented by selected from~~ alkenyl, alkoxy, alkoxy carbonyl, alkyl carbonyl, alkyl carbonyloxy, alkylendioxy, alkylsulfinyl, alkylsulfonyl, alkylthio, alkynyl, amino, aminocarbonyl, aryl, arylalkenyl, arylalkyloxy, aryloxy, aryloxy carbonyl, arylsulfinyl, arylsulfonyl, arylthio, carboxy, cyano, formyl, halogen, haloalkoxy, heterocyclyl, hydroxy, mercapto, ~~or and~~ nitro, appended to any carbon atom of the alkyl moiety;
- ii) the term "alkenyl" or "lower alkenyl", used alone or in any combination, refers to a straight or branched hydrocarbon chain containing 2-8 carbon atoms with at least one carbon-carbon double bond represented by  $R_aR_bC=CR_cR_d$ , wherein Ra-Rd refer to substituents, each individually and independently ~~represented by selected from~~ hydrogen, alkyl, alkoxy, ~~or and~~ alkoxyalkyl;
- iii) the term "alkoxy", used alone or in any combination, refers to an alkyl group appended to the parent molecular moiety through an oxygen bridge;
- iv) the term "aryl", used alone or in any combination, refers to a carbocyclic group having at least one aromatic ring of phenyl, biphenyl, or multiple condensed ring systems, in which at least one ring is aromatic, ~~wherein the multiple condensed ring systems are represented by selected from the group consisting of~~ 1,2,3,4-tetrahydronaphthyl, naphthyl, anthryl, phenanthryl, ~~or and~~ fluorenyl, which aryl group may be optionally substituted with one or more functional groups individually and independently ~~represented by selected from~~ alkenyl, alkoxy, alkoxyalkyl, alkoxy carbonyl, alkoxy carbonylalkyl, alkyl, alkyl carbonyl, alkyl carbonylalkyl, alkyl carbonyloxy, alkylendioxy, alkylsulfinyl, alkylsulfinylalkyl, alkylsulfonyl, alkylsulfonylalkyl, alkylthio, alkylthioalkyl,

- alkynyl, amino, aminoalkyl, aminocarbonyl, aminocarbonylalkyl, aryl, arylalkenyl, arylalkyloxy, arylalkyl, aryloxy, aryloxy carbonyl, aryloxy carbonylalkyl, arylsulfinyl, arylsulfinylalkyl, arylsulfonyl, arylsulfonylalkyl, arylthio, arylthioalkyl, carboxy, carboxyalkyl, cyano, cyanoalkyl, formyl, formylalkyl, halogen, haloalkoxy, haloalkyl, heteroaryl, heterocyclyl, hydroxy, hydroxyalkyl, mercapto, ~~or~~ and nitro;
- v) the term "arylalkoxy", used alone or in any combination, refers to an aryl group which may be unsubstituted or substituted as previously defined and which is appended to the parent molecular moiety through an alkoxy group;
- vi) the term "arylalkyl", used alone or in any combination, refers to an aryl group which may be unsubstituted or substituted as previously defined and which is appended to the parent molecular moiety through an alkyl group;
- vii) the term "aryloxy", used alone or in any combination, refers to an aryl group which may be unsubstituted or substituted as previously defined and which is appended to the parent molecular moiety through an oxygen bridge;
- viii) the term "arylcarbonyl" or "aroyl", used alone or in any combination, refers to an aryl group appended to the parent molecular moiety through a carbonyl group;
- ix) the term "cycloalkyl", used alone or in any combination, refers to a saturated cyclic hydrocarbon moiety containing 3-15 carbon atoms, optionally substituted with one or more groups, each individually and independently represented by selected from alkenyl, alkoxy, alkoxyalkyl, alkoxy carbonyl, alkoxy carbonylalkyl, alkyl, alkylcarbonyl, alkylcarbonylalkyl, alkylcarbonyloxy, alkylendioxy, alkylsulfinyl, alkylsulfinylalkyl, alkylsulfonyl, alkylsulfonylalkyl, alkylthio, alkylthioalkyl, alkynyl, amino, aminoalkyl, aminocarbonyl, aminocarbonylalkyl, aryl, arylalkenyl, arylalkyloxy, arylalkyl, aryloxy, aryloxy carbonyl, aryloxy carbonylalkyl, arylsulfinyl, arylsulfinylalkyl, arylsulfonyl, arylsulfonylalkyl, arylthio, arylthioalkyl, carboxy, carboxyalkyl, cyano, cyanoalkyl, formyl, formylalkyl, halogen, haloalkoxy, haloalkyl, heterocyclyl, hydroxy, hydroxyalkyl, mercapto, ~~or~~ and nitro, provided that a distal ring of the polycyclic cycloalkyl group's one of the distal rings may be aromatic;

- x) the term "heterocyclyl" alone or in any combination, refers to a monocyclic, bicyclic or polycyclic ring system containing up to 15 ring atoms, at least one of these being a hetero atom independently ~~represented by selected from~~ nitrogen, oxygen ~~or and~~ sulfur, which ring system may be saturated, partially unsaturated, unsaturated or aromatic and may be optionally substituted with one or more groups, each individually and independently ~~represented by selected from~~ alkenyl, alkoxy, alkoxyalkyl, alkoxycarbonyl, alkoxycarbonylalkyl, alkyl, alkylcarbonyl, alkylcarbonylalkyl, alkylcarbonyloxy, alkylendioxy, alkylsulfinyl, alkylsulfinylalkyl, alkylsulfonyl, alkylsulfonylalkyl, alkylthio, alkylthioalkyl, alkynyl, amino, aminoalkyl, aminocarbonyl, aminocarbonylalkyl, aryl, arylalkenyl, arylalkyloxy, arylalkyl, aryloxy, aryloxy carbonyl, aryloxy carbonylalkyl, arylsulfinyl, arylsulfinylalkyl, arylsulfonyl, arylsulfonylalkyl, arylthio, arylthioalkyl, carboxy, carboxyalkyl, cyano, cyanoalkyl, cycloalkyl, formyl, formylalkyl, halogen, haloalkoxy, haloalkyl, heterocyclyl, heteroaryl, hydroxy, hydroxyalkyl, mercapto, ~~or and~~ nitro; and
- xi) the term "heteroaryl", used alone or in any combination, is a special case of heterocyclyl and refers to a mono- or bicyclic or polycyclic aromatic ring system, in which at least one heterocyclic ring is aromatic.

17. (New) The composition of claim 12, wherein the composition comprises an optically pure enantiomer, a mixture of enantiomers, a racemate, an optically pure diastereoisomer, a mixtures of diastereoisomers, a diastereoisomeric racemate, a mixture of diastereoisomeric racemates, a meso form, a geometric isomer, a prodrug form, a solvate or a morphological form of the compound.

18. (New) The method for preventing or treating chronic or acute allergic immune disorder of claim 13, wherein the disorder comprises allergic asthma, rhinitis, chronic obstructive pulmonary disease (COPD), dermatitis, inflammatory bowel disease, rheumatoid arthritis, allergic nephritis, conjunctivitis, atopic dermatitis, bronchial asthma, food allergy, systemic mast cell disorders, anaphylactic shock, urticaria, eczema, itching, inflammation, ischemia-reperfusion injury, cerebrovascular disorders, pleuritis, ulcerative colitis, Churg-Strauss syndrome, sinusitis, basophilic leukemia, or basophilic leukocytosis.

19. (New) The compound of claim 4, wherein the compound is {3-[(E)-2-cyano-3-(3,4-dihydro-2H-quinolin-1-yl)-3-oxo-propenyl]-indol-1-yl}-acetic acid.
20. (New) The compound of claim 4, wherein:
- ❖ A is cyano;
  - ❖ B is hydrogen or methyl;
  - ❖  $R^1$ ,  $R^2$ ,  $R^3$  and  $R^4$  are all hydrogen atoms or one of  $R^1$ ,  $R^2$ ,  $R^3$  and  $R^4$  is halogen while the others are all hydrogen; and
  - ❖ at least one of  $R^5$  and  $R^6$  is chosen from the group consisting of heteroaryl, heteroaryl-alkyl, diphenylalkyl, aryl, aryl-alkoxy-aryl, aryl-alkyl, aryl-alkyl-aryl, arylcarbonyl-aryl and aryloxy-aryl; or  $R^5$  and  $R^6$ , together with the nitrogen atom to which they are attached, form a heterocyclic ring system.
21. (New) A method for preventing or treating a chronic or acute allergic immune disorder, comprising administering to a subject in need thereof an effective amount of the compound according to claim 20.
22. (New) The method for preventing or treating a chronic or acute allergic immune disorder of claim 21, wherein the disorder comprises allergic asthma, rhinitis, chronic obstructive pulmonary disease (COPD), dermatitis, inflammatory bowel disease, rheumatoid arthritis, allergic nephritis, conjunctivitis, atopic dermatitis, bronchial asthma, food allergy, systemic mast cell disorders, anaphylactic shock, urticaria, eczema, itching, inflammation, ischemia-reperfusion injury, cerebrovascular disorders, pleuritis, ulcerative colitis, Churg-Strauss syndrome, sinusitis, basophilic leukemia, or basophilic leukocytosis.
23. (New) A method for preventing or treating a chronic or acute allergic immune disorder, comprising administering to a subject in need thereof an effective amount of the compound according to claim 10.
24. (New) The method for preventing or treating a chronic or acute allergic immune disorder of claim 23, wherein the disorder comprises allergic asthma, rhinitis, chronic obstructive pulmonary disease (COPD), dermatitis, inflammatory bowel disease, rheumatoid arthritis, allergic nephritis, conjunctivitis, atopic dermatitis, bronchial asthma, food allergy, systemic mast cell disorders, anaphylactic shock, urticaria, eczema, itching, inflammation, ischemia-

reperfusion injury, cerebrovascular disorders, pleuritis, ulcerative colitis, Churg-Strauss syndrome, sinusitis, basophilic leukemia, or basophilic leukocytosis.